ICU Medical Q2 Adjusted EPS of $2.37 Beats Sharply, FY2026 Outlook Raised

ICUI reported second-quarter adjusted earnings of $2.37 per share, well ahead of the roughly $1.91 to $1.95 consensus depending on the estimate source, a beat in the $0.42 to $0.46 range. Revenue of $547.9 million topped the roughly $544.1 million street figure, up 6% organically though only 1% on a reported basis.

The gap between 6% organic and 1% reported growth is the detail worth holding. It means portfolio actions and currency are masking underlying demand that is running considerably better than the headline suggests, which is typically a setup where the reported figure catches up as comparisons ease.

Management raised full-year 2026 guidance materially: adjusted EPS to $8.60 to $9.00, up from a prior $7.75 to $8.45, and adjusted EBITDA to $415 million to $435 million from $400 million to $430 million. Adjusted EBITDA in the quarter was $110 million, up 10% year over year. Shares gained roughly 4.75% following the release.

The size of the EPS guidance raise, roughly 70 cents at the midpoint against a quarterly beat of about 45 cents, indicates management is extrapolating the margin improvement rather than treating it as a one-quarter item. What to watch is gross margin, which the raised outlook implies runs near 41.5%, and whether the organic growth rate holds at 6% once the portfolio comparisons normalize.

Related Stocks

• ICUI